Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given an average rating of “Buy” by the six research firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have covered the stock in the last year is $21.00.

Separately, HC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 price target for the company.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $5.10 on Friday. The business has a 50 day simple moving average of $5.59 and a 200 day simple moving average of $9.73. Artiva Biotherapeutics has a 12-month low of $3.37 and a 12-month high of $17.31.

Institutional Trading of Artiva Biotherapeutics

Several large investors have recently added to or reduced their stakes in the business. Deutsche Bank AG bought a new position in shares of Artiva Biotherapeutics in the fourth quarter worth $216,000. BNP Paribas Financial Markets grew its position in Artiva Biotherapeutics by 262.1% in the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock valued at $100,000 after buying an additional 7,151 shares in the last quarter. Northern Trust Corp increased its stake in Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after buying an additional 4,335 shares during the period. Barclays PLC increased its stake in Artiva Biotherapeutics by 23.2% during the 4th quarter. Barclays PLC now owns 24,161 shares of the company’s stock valued at $244,000 after buying an additional 4,545 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after buying an additional 3,361 shares in the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.